Wachterman MW, Corneau EE, O’Hare AM, Keating NL, Mor V. Association of hospice payer with concurrent receipt of hospice and dialysis among US veterans with end-stage kidney disease: a retrospective analysis of a national cohort. *JAMA Health Forum*. 2022;3(10):e223708. doi:10.1001/jamahealthforum.2022.3708

**eTable 1.** Concurrent Dialysis Payer by Primary Hospice Diagnosis Among Medicare-Financed Concurrent Hospice Users

**eTable 2.** Concurrent Hospice Utilization and Hospice Length of Stay Among VA-Enrolled Veterans Who Had Received Maintenance Dialysis Who Received Medicare-Financed Hospice by Setting of Hospice Care

**eFigure.** Unadjusted Proportions of VA-Enrolled Hospice Users Receiving Concurrent Care by Hospice Payer, Overall and Stratified by Dominant Dialysis Payer

This supplemental material has been provided by the authors to give readers additional information about their work.
**eTable 1. Concurrent Dialysis Payer by Primary Hospice Diagnosis Among Medicare-Financed Concurrent Hospice Users**

| Concurrent dialysis payer | All (N=4050) | ESKD\(^a\) Primary Diagnosis (N=255, 6.3%) | Non-ESKD\(^a\) primary diagnosis (N=3795, 93.7%) |
|---------------------------|--------------|--------------------------------------------|-------------------------------------------------|
| Medicare-Financed         | 567 (14.0)   | 36 (14.1)                                  | 531 (14.0)                                      |
| VA-Community Financed     | 3215 (79.4)  | 199 (78.0)                                 | 3016 (79.5)                                     |
| VA-Financed               | 268 (6.6)    | 20 (7.8)                                   | 248 (6.5)                                       |

\(^a\) End-stage kidney disease
eTable 2. Concurrent Hospice Utilization and Hospice Length of Stay Among VA\textsuperscript{a}-
Enrolled Veterans Who Had Received Maintenance Dialysis Who Received Medicare-
Financed Hospice by Setting of Hospice Care

| e2a. Concurrent Hospice Use by Setting of Medicare-Financed Hospice Care (N=16465) | Total Medicare-Financed Hospice (N=16465) | Medicare-Financed Home Hospice (N=14312, 86.9%) | Medicare-Financed Inpatient Hospice (N=2153, 13.1%) |
|---------------------------------|------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Concurrent care use             |                                          |                                               |                                               |
| Unadjusted, % (N)              | 4050 (24.6)                              | 3755 (26.2)                                   | 295 (13.7)                                    |
| Adjusted,\textsuperscript{b} % (95% CI) | 24.9 (24.3, 25.6)                     | 26.2 (25.5, 26.9)                             | 14.6 (12.9, 16.4)                             |

| e2b. Hospice Length of Stay by Setting of Medicare-Financed Hospice Care (N=16465) | Overall, days | Non-concurrent hospice, days | Concurrent hospice, Days |
|---------------------------------------------------------------------------------|---------------|-----------------------------|--------------------------|
| Hospice length of stay, median (IQR)                                             | 5 (15)        | 4 (6)                       | 47 (147)                 |
| Non-concurrent hospice, days                                                     | 6 (17)        | 4 (6)                       | 50 (156)                 |
| Concurrent hospice, Days                                                         | 4 (7)         | 4 (5)                       | 28 (59)                  |

\textsuperscript{a} VA, Veterans Health Administration
\textsuperscript{b} Adjusted for age, sex, race, rurality, proximity to nearest VA Medical Center, and VISN fixed effects
\textsuperscript{c} P<0.001 for comparison versus Medicare-financed hospice
eFigure. Unadjusted Proportions of VA\textsuperscript{a}-Enrolled Hospice Users Receiving Concurrent Care by Hospice Payer, Overall and Stratified by Dominant Dialysis Payer\textsuperscript{b}

| Overall Dialysis Type | Concurrent Care (%) |
|-----------------------|---------------------|
| Overall Dialysis      |                     |
| Medicare-financed    | 24.0                |
| VA Community Care-financed | 24.5          |
| VA-financed dialysis | 46.7                |
| VA                     | 24.6                |
| Overall Dialysis Type |                     |
| Medicare-financed    | 58.2                |
| VA Community Care-financed | 56.2          |
| VA-financed dialysis | 58.7                |
| VA                     | 60.8                |
| By Dominant Dialysis Type |                 |
| Medicare-financed    | 66.3                |
| VA Community Care-financed | 63.6          |
| VA-financed dialysis |                     |
| VA                     |                     |

Notes: VA dialysis = dialysis in a VA dialysis facility; Medicare-financed dialysis = dialysis in a non-VA dialysis facility paid for by Medicare; VA Community Care-financed dialysis = dialysis in a non-VA dialysis facility paid for by the VA; Medicare hospice = community-based hospice services paid for by Medicare; VA Community Care-financed hospice = community-based hospice services paid for by the VA; VA inpatient hospice = hospice services in a VA inpatient facility.

\textsuperscript{a} Veterans Health Administration; \textsuperscript{b} Payer that financed the greatest number of dialysis treatments.